Disease · MONDO_0018177
Comparisons in its trials156
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 156
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bevacizumab + RT+Temozolomide vs Placebo + RT+Temozolomide: serious adverse events | 179 of 461 | 115 of 450 | 911 | NCT00943826 | Trial comparisons |
| Radiotherapy, Temozolomide Plus Nivolumab vs Radiotherapy, Temozolomide Plus Placebo: deaths from any cause | 263 of 358 | 255 of 358 | 716 | NCT02667587 | Trial comparisons |
| Radiotherapy, Temozolomide Plus Nivolumab vs Radiotherapy, Temozolomide Plus Placebo: serious adverse events | 259 of 355 | 217 of 354 | 709 | NCT02667587 | Trial comparisons |
| Experimental Arm vs Standard Arm: deaths from any cause | 55 of 309 | 57 of 307 | 616 | NCT03345095 | Trial comparisons |
Randomized Arm 1: TMZ+RT + Placebo vs Randomized Arm 2: TMZ+RT + Bevacizumab: Incidence of Grade 3 and Higher Treatment-related Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 3.0 | 87 of 300 | 97 of 303 | 603 | NCT00884741 | Trial comparisons |
| Experimental Arm vs Standard Arm: serious adverse events | 114 of 305 | 80 of 297 | 602 | NCT03345095 | Trial comparisons |
| Nivolumab + Radiation Therapy vs Temozolomide + Radiation Therapy: deaths from any cause | 269 of 280 | 253 of 280 | 560 | NCT02617589 | Trial comparisons |
| Nivolumab + Radiation Therapy vs Temozolomide + Radiation Therapy: serious adverse events | 206 of 278 | 141 of 275 | 553 | NCT02617589 | Trial comparisons |
| Temozolomide vs Radiation: serious adverse events | 158 of 271 | 135 of 271 | 542 | NCT00482677 | Trial comparisons |
| Cilengitide + Temozolomide + Radiotherapy vs Temozolomide + Radiotherapy: serious adverse events | 138 of 263 | 115 of 258 | 521 | NCT00689221 | Trial comparisons |
| Optune System Combined With Temozolomide (TMZ) + Pembrolizumab vs Historical Control Optune System Combined With Temozolomide (TMZ): deaths from any cause | 25 of 28 | 265 of 466 | 494 | NCT03405792 | Trial comparisons |
| Optune System Combined With Temozolomide (TMZ) + Pembrolizumab vs Historical Control Optune System Combined With Temozolomide (TMZ): serious adverse events | 18 of 28 | 0 of 456 | 484 | NCT03405792 | Trial comparisons |
| Arm II (Temozolomide, Veliparib) vs Arm I (Temozolomide, Placebo): deaths from any cause | 183 of 218 | 175 of 213 | 431 | NCT02152982 | Trial comparisons |
| Arm II (Temozolomide, Veliparib) vs Arm I (Temozolomide, Placebo): serious adverse events | 43 of 218 | 47 of 213 | 431 | NCT02152982 | Trial comparisons |
| Arm II (Temozolomide, Veliparib) vs Arm I (Temozolomide, Placebo): Objective Tumor Response | 37 of 119 | 34 of 118 | 237 | NCT02152982 | Trial comparisons |
| Imatinib 600 mg + Hydroxyurea 1000 mg vs Imatinib 1000 mg + Hydroxyurea 1000 mg: serious adverse events | 62 of 131 | 53 of 99 | 230 | NCT00290771 | Trial comparisons |
| Treatment Group A (175 mg) vs Treatment Group B + Group C (125 mg): deaths from any cause | 41 of 46 | 144 of 176 | 222 | NCT00704288 | Trial comparisons |
| Treatment Group A (175 mg) vs Treatment Group B + Group C (125 mg): serious adverse events | 24 of 46 | 90 of 176 | 222 | NCT00704288 | Trial comparisons |
| Test Group vs Control Group: deaths from any cause | 51 of 91 | 52 of 89 | 180 | NCT00807027 | Trial comparisons |
| Test Group vs Control Group: serious adverse events | 35 of 91 | 31 of 89 | 180 | NCT00807027 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018177/comparisons